Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(11):1601–1604. doi: 10.1038/bjc.1997.273

Dissociation of bone formation markers in bone metastasis of prostate cancer.

M Koizumi 1, H Maeda 1, K Yoshimura 1, T Yamauchi 1, T Kawai 1, E Ogata 1
PMCID: PMC2223543  PMID: 9184174

Abstract

To clarify the meaning and clinical value of bone formation markers in bone metastasis from prostate cancer, we investigated the bone formation markers carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BA1-p) and osteocalcin, so-called bone gla protein (BGP) in 43 prostate cancer patients with and 46 patients without overt bone metastasis. Patients with bone metastasis were evaluated repeatedly by bone scan at intervals of 3-6 months. The expression patterns of bone formation markers in patients with progression of bone metastasis became dissociated; BA1-p and PICP were elevated in patients with progression of bone metastasis but BGP was not. Instead, BGP showed slight elevation in patients with improvement and complete remission of bone metastasis. PICP, BA1-p and BGP are all bone formation markers, but each marker appears in a different phase of bone formation: PICP appears in proliferation phase, BA1-p appears in matrix maturation phase and BGP appears in late bone formation phase. Our findings that BGP was not elevated in progression of bone metastasis and that it increased slightly with improvement and complete remission of bone metastasis may imply that the bone formation that occurs in blastic bone metastasis is different from normal bone formation.

Full text

PDF
1601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki J., Yamamoto I., Hino M., Shigeno C., Kitamura N., Itoh H., Torizuka K., Itoh T., Furuta M. Sclerotic bone metastasis: radiologic-pathologic correlation. Radiology. 1986 Apr;159(1):127–132. doi: 10.1148/radiology.159.1.3952298. [DOI] [PubMed] [Google Scholar]
  2. Arai Y., Takeuchi H., Oishi K., Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate. 1992;20(3):169–177. doi: 10.1002/pros.2990200302. [DOI] [PubMed] [Google Scholar]
  3. Calvo M. S., Eyre D. R., Gundberg C. M. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996 Aug;17(4):333–368. doi: 10.1210/edrv-17-4-333. [DOI] [PubMed] [Google Scholar]
  4. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., Smith E., Bonadio J., Goldstein S., Gundberg C. Increased bone formation in osteocalcin-deficient mice. Nature. 1996 Aug 1;382(6590):448–452. doi: 10.1038/382448a0. [DOI] [PubMed] [Google Scholar]
  5. Francini G., Bigazzi S., Leone V., Gennari C. Serum osteocalcin concentration in patients with prostatic cancer. Am J Clin Oncol. 1988;11 (Suppl 2):S83–S87. doi: 10.1097/00000421-198801102-00021. [DOI] [PubMed] [Google Scholar]
  6. Francini G., Petrioli R., Manganelli A., Cintorino M., Marsili S., Aquino A., Mondillo S. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 1993 Jun;67(6):1430–1436. doi: 10.1038/bjc.1993.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Koizumi M., Yamada Y., Takiguchi T., Nomura E., Furukawa M., Kitahara T., Yamashita T., Maeda H., Takahashi S., Aiba K. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol. 1995;121(9-10):542–548. doi: 10.1007/BF01197767. [DOI] [PubMed] [Google Scholar]
  8. Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995 May;71(5):1061–1064. doi: 10.1038/bjc.1995.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997 Feb;157(2):539–543. [PubMed] [Google Scholar]
  10. Pollen J. J., Witztum K. F., Ashburn W. L. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984 Apr;142(4):773–776. doi: 10.2214/ajr.142.4.773. [DOI] [PubMed] [Google Scholar]
  11. Price P. A., Williamson M. K., Haba T., Dell R. B., Jee W. S. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7734–7738. doi: 10.1073/pnas.79.24.7734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Risteli L., Risteli J. Biochemical markers of bone metabolism. Ann Med. 1993 Aug;25(4):385–393. doi: 10.3109/07853899309147301. [DOI] [PubMed] [Google Scholar]
  13. Sano M., Kushida K., Takahashi M., Ohishi T., Kawana K., Okada M., Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994 Oct;70(4):701–703. doi: 10.1038/bjc.1994.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shih W. J., Wierzbinski B., Collins J., Magoun S., Chen I. W., Ryo U. Y. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J Nucl Med. 1990 Sep;31(9):1486–1489. [PubMed] [Google Scholar]
  15. Slack N. H., Murphy G. P. Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am. 1984 May;11(2):337–342. [PubMed] [Google Scholar]
  16. Stein G. S., Lian J. B., Owen T. A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 1990 Oct;4(13):3111–3123. doi: 10.1096/fasebj.4.13.2210157. [DOI] [PubMed] [Google Scholar]
  17. Zhou H., Choong P., McCarthy R., Chou S. T., Martin T. J., Ng K. W. In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res. 1994 Sep;9(9):1489–1499. doi: 10.1002/jbmr.5650090922. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES